Status: Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Participants needed: 1,650
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Akero Therapeutics, IncUpdated: Jun 25, 2026Locations: 356
Eligibility criteria
Males and non-pregnant, non-lactating females between 18 - 80 years of age inclu... [+5]
Other causes of liver disease based on medical history and/or liver histology an... [+2]